Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Adenosine Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 9/20 | 0.81 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.81 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.81 |
| ▸ | SRC | P12931 | 2/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.81 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.81 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.81 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.81 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.81 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.81 |
| ▸ | LDHA | P00338 | 1/20 | 0.81 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.81 |
| ▸ | FBP1 | P09467 | 1/20 | 0.81 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.81 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.81 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.81 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.81 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Phosphate SCHEMBL29724022 | 1.00 | P2RY1 (0.81) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL1356934 | 0.99 | P2RY1 (0.83) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL145417 | 0.99 | P2RY1 (0.83) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL29364783 | 0.99 | P2RY1 (0.83) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL353218 | 0.99 | P2RY1 (0.83) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL23093554 | 0.98 | P2RY1 (0.81) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL5600449 | 0.98 | P2RY1 (0.81) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL9068130 | 0.98 | P2RY1 (0.81) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL1164224 | 0.98 | P2RY1 (0.81) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL7064977 | 0.98 | P2RY1 (0.81) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041078-A1 | METHODS AND COMPOSITIONS FOR IMPROVED TASTE QUALITY | ALMENDRA PTE LTD (SG) | 2024-02-08 | — | — | US | claimed |
| EP-4282282-A2 | METHODS AND COMPOSITIONS FOR IMPROVED TASTE QUALITY | Almendra Pte. Ltd. (SG) | 2023-11-29 | — | — | EP | claimed |
| EP-4009810-B1 | METHODS AND COMPOSITIONS FOR IMPROVED TASTE QUALITY | ALMENDRA PTE LTD (SG) | 2023-06-21 | — | — | EP | claimed |
| CN-115334899-A | Methods and compositions for improving taste quality | 阿尔门德拉私人有限公司 | 2022-11-11 | — | — | CN | claimed |
| WO-2022127326-A1 | PROTEIN AND MULTI-STAGE POROUS METAL-ORGANIC FRAMEWORK COMPLEX, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 华南理工大学 | 2022-06-23 | — | — | WO | claimed |
| EP-4009810-A1 | METHODS AND COMPOSITIONS FOR IMPROVED TASTE QUALITY | Almendra Pte. Ltd. (SG) | 2022-06-15 | — | — | EP | claimed |
| CN-113101908-A | Hybrid ligand hierarchical pore metal organic framework material and preparation method and application thereof | 华南理工大学 | 2021-07-13 | — | — | CN | claimed |
| CN-112707966-A | Protein and hierarchical pore metal-organic framework compound and preparation method and application thereof | 华南理工大学 | 2021-04-27 | — | — | CN | claimed |
| WO-2021064616-A1 | METHODS AND COMPOSITIONS FOR IMPROVED TASTE QUALITY | Almendra Pte. Ltd (SG) | 2021-04-08 | — | — | WO | claimed |
| US-20210092986-A1 | METHODS AND COMPOSITIONS FOR IMPROVED TASTE QUALITY | ALMENDRA PTE. LTD. (SG) | 2021-04-01 | — | — | US | claimed |
| US-6583258-B1 | Transesterification catalyst is a salt of adenosine 5'-monophosphate or 2-deoxy-6-phosphogluconic acid; diaryl carbonate with a dihydroxy aromatic compound; bisphenol A with diphenyl carbonate | GENERAL ELECTRIC COMPANY | 2003-06-24 | — | — | US | claimed |
| US-20240114942-A1 | Antagonists of T2R54 and Compositions and Uses Thereof | FIRMENICH INCORPORATED (US) | 2024-04-11 | — | — | US | disclosed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240041078-A1 | METHODS AND COMPOSITIONS FOR IMPROVED TASTE QUALITY | ALMENDRA PTE LTD (SG) | 2024-02-08 | — | — | US | disclosed |
| US-11871772-B2 | Antagonists of T2R54 and compositions and uses thereof | FIRMENICH INCORPORATED (US) | 2024-01-16 | — | — | US | disclosed |
| US-7182939-B2 | Hair tonic composition | SHISEIDO COMPANY, LTD. (JP) | 2007-02-27 | — | — | US | disclosed |
| EP-0998907-B1 | Hair tonic composition comprising adenosine | SHISEIDO CO LTD (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-6583258-B1 | Transesterification catalyst is a salt of adenosine 5'-monophosphate or 2-deoxy-6-phosphogluconic acid; diaryl carbonate with a dihydroxy aromatic compound; bisphenol A with diphenyl carbonate | GENERAL ELECTRIC COMPANY | 2003-06-24 | — | — | US | disclosed |
| US-20020192177-A1 | Hair tonic composition | A. AOKI, ISHIDA & ASSOCIATES | 2002-12-19 | — | — | US | disclosed |
| EP-0998907-A1 | Hair tonic composition comprising adenosine | SHISEIDO COMPANY LIMITED (JP) | 2000-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | P2RY1 628/4885P2RY11 1375/4885P2RY2 1065/4885 |
| US-11871772-B2 | Antagonists of T2R54 and compositions and uses thereof | TAS2R50, TAS2R30, TAS2R60 | P2RY1 131/4885P2RY11 196/4885P2RY2 69/4885 |
| US-20240114942-A1 | Antagonists of T2R54 and Compositions and Uses Thereof | TAS2R50, TAS2R30, TAS2R60 | P2RY1 131/4885P2RY11 196/4885P2RY2 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.